GHK-Cu and the Hair Follicle: What a Tripeptide-Copper Complex Does in the Literature

GHK-Cu is three amino acids and a copper ion, and it carries a reputation in hair care that is larger than its hair literature. The tripeptide glycyl-histidyl-lysine was isolated from human plasma in the 1970s, its copper complex has been studied in skin and wound models for four decades, and it appears in compounded formularies as a 1% scalp solution and as a family of creams and serums. The FDA has not approved GHK-Cu for hair loss or any form of alopecia, no randomised trial of GHK-Cu in human pattern hair loss has been published, and the follicle study most often cited for copper peptides used a structural relative. A practice that sources a copper peptide formulation is well served by knowing which of those sentences applies to which claim.

This article sets out what the molecule is, what the gene-expression and wound literature reports, what the hair-specific evidence contains and which peptide it studied, why copper peptides are paired with microneedling, and the regulatory position, which turns on the route of administration. It attributes every finding to the study that reported it, makes no claim about what any formulation does, and leaves the prescribing decision where it belongs.

A courier with a copper badge: what the molecule is

GHK is glycine, histidine and lysine in that order, a fragment of a larger protein rather than a hormone in its own right, with a mass of roughly 340 daltons as the free peptide. Its histidine and its terminal amine bind copper(II) with high affinity, and in tissue it exists largely as the complex written GHK-Cu. An analogy that holds for the chemistry and not for any effect is a courier who can only enter certain buildings while wearing a badge: the peptide is the courier and the copper is the badge, and most of what is written about GHK concerns the badged form.

Plasma concentrations of the peptide have been reported to fall with age, an observation the 2015 review by Pickart and colleagues in BioMed Research International uses to frame it as a natural modulator of skin repair. The review is candid that the observation motivates the research rather than proving anything about ageing, and a reader who keeps that distinction will read the rest of the literature more accurately.

The literature is mostly about skin, wounds and gene expression

The 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences is the standard entry point to the field. It summarises gene-expression work in which GHK was reported to change the expression of a large fraction of human genes in cultured cells, and it collects the in vitro and animal literature described in the context of collagen and glycosaminoglycan synthesis, angiogenesis, anti-inflammatory signalling and wound models. The gene-expression claim traces back to a 2012 Genome Medicine study by Campbell and colleagues that identified a signature of emphysema-related lung destruction and reported its reversal by GHK in a computational and cell-based analysis, which is worth knowing because it was a lung study and not a skin one.

The animal work is where mechanism meets a measurable outcome. A 2013 study in Otolaryngology, Head and Neck Surgery examined a topical copper tripeptide complex in an irradiated rat wound model, and a 2015 study in the Journal of Orthopaedic Research examined GHK-Cu in a rat model of anterior cruciate ligament reconstruction and reported a transient effect on healing outcome. A 2026 study by Hu and colleagues in the European Journal of Pharmacology examined the anti-inflammatory signalling in a zebrafish larvae model, and a 2026 study by Jeon and colleagues in Antioxidants examined a plant-extract and GHK-Cu complex in keratinocytes. Mokhtar and colleagues reviewed the aesthetic literature in Aesthetic Surgery Journal in 2026. All of it is preclinical or review, none of it concerns hair, and the evidence page on GHK-Cu under the Science section of this site labels each citation with its design.

The hair evidence is a related peptide in organ culture and a 1993 primate report

The study most often cited for copper peptides and hair is Pyo and colleagues, published in Archives of Pharmacal Research in 2007. Using human hair follicles in organ culture and cultured dermal papilla cells, the authors reported that a tripeptide-copper complex elongated the follicles, increased dermal papilla cell proliferation and reduced markers of programmed cell death in those cells at picomolar to nanomolar concentrations. It is a careful study and it is the strongest hair-specific evidence in the field.

The peptide in that study was AHK-Cu, alanyl-histidyl-lysine complexed with copper, which differs from GHK-Cu in its first residue. The two share a copper-binding motif and are often discussed together, and the finding is genuinely relevant to the class. It is not a finding about GHK-Cu, and a page that cited it as one would be substituting one molecule for another in the way the TB-500 evidence page on this site describes for thymosin beta-4. Uno and Kurata reported follicle effects of copper-binding peptides in a macaque model in a 1993 supplement of the Journal of Investigative Dermatology; that report is now more than thirty years old and has not been followed by a controlled human trial of GHK-Cu for hair.

• Organ culture: human follicles and dermal papilla cells with AHK-Cu, reported in 2007.
• Animal model: copper-binding peptides in a macaque model, reported in 1993.
• Reviews: the 2015 and 2018 reviews summarise gene-expression, wound and skin literature; hair is a minor part.
• Human trials in pattern hair loss: none published for GHK-Cu.

Why copper peptides are paired with microneedling

A hydrophilic tripeptide-copper complex does not cross intact stratum corneum readily, which is why delivery is its own research question. A 2015 study in Pharmaceutical Research examined microneedle-mediated delivery of copper peptide through skin, and a 2025 review by Ogórek and colleagues in Molecules asked whether the field is ready to measure skin permeation of liposomal GHK-Cu at all. Both are about getting the molecule where a formulator wants it rather than about what it does once there, and they are the mechanistic background to the pairing of copper peptide formulations with microneedling in aesthetic practice.

The clinic-launch guide on topical application and microneedling on this site explains the device line: a cleared microneedling device is cleared to needle, not to deliver, and the pairing is a practitioner decision that the device clearance does not cover. The scalp microneedling article later in this series takes the procedure literature at its own level of detail.

The route decides the regulatory position

FDA placed GHK-Cu for injectable routes of administration in category 2 of its interim policy on bulk drug substances for compounding under section 503A, meaning the agency identified significant safety risks, and the nomination was withdrawn by the nominator in April 2026. FDA now carries the substance under nominations withdrawn and still publishes the rationale it wrote, and a withdrawn nomination leaves the substance on no 503A list for any route. The agency’s stated rationale concerns immunogenicity risk from aggregation and peptide-related impurities in injectable preparations and the limited human data available to inform safety considerations, and the entry is written for injectable routes. A topical scalp solution or a cream is prepared by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, against an individual prescription, and whether and on what basis the pharmacy compounds it is the pharmacy’s determination under that board’s oversight, which this article does not make.

It remains a compounded prescription product. The 1% scalp solution and the GHK-Cu creams and serums are prepared under section 503A to an individual prescription and have not been evaluated by the FDA for safety, effectiveness or quality, and the FDA’s own questions and answers on compounding say so in general terms. Cosmetic-grade copper peptide products marketed without disease claims sit in a separate regulatory lane again. ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance, and the product pages on this site list the topical formulations by composition and dating only.

Closing Observation

GHK-Cu has one of the largest literatures of any peptide in skin science and one of the smallest in hair, and the two are routinely presented as though they were the same. The gene-expression, wound and animal work is real and is summarised in two reviews by the peptide’s principal investigator; the hair evidence is a related molecule in organ culture and a primate report from the early 1990s; and no randomised trial of GHK-Cu in human pattern hair loss exists. The regulatory position follows the route, with an FDA entry for the injectable, placed in category 2 and since withdrawn, and compounded prescription status for the topical formulations prepared by a licensed 503A pharmacy under its state board’s oversight.

What the literature does not support is the transfer of the skin reputation to the scalp solution without the evidence to carry it. A practice that reads the field this way will describe a copper peptide formulation to its patients in the terms the organ-culture and animal work allow, will keep the injectable and the topical in separate regulatory boxes, and will be considerably harder to sell a vial to on the strength of a molecule’s reputation in a different tissue.